FK-866

Nicotinamide phosphoribosyltransferase inhibitor

FK-866

Nicotinamide phosphoribosyltransferase inhibitor

From: 143 USD
Catalog #
(Select a product)
Nicotinamide phosphoribosyltransferase inhibitor
Add to Wish List

Overview

FK-866 is a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme that regulates NAD+ biosynthesis from the natural precursor nicotinamide (Cameron et al.; Hasmann & Schemainda). In hepatocarcinoma cells, FK-866 activates AMP-activated protein kinase (AMPK) and downregulates mammalian target of rapamycin (mTOR) signaling (Schuster et al.).

METABOLISM
· FK-866 can be used to deplete NAD+, a central metabolism cofactor (Cameron et al.; Hasmann & Schemainda; Jadeja et al.).

CANCER RESEARCH
· Depletes NAD+ and induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC₅₀ = ~1 nM; Hasmann & Schemainda).
· Triggers dose-dependent cytotoxicity in multiple myeloma cells (Cea et al.).
· Induces autophagic death in neuroblastoma SH-SY5Y cells (IC₅₀ = 0.93 nM; Billington et al.).
Alternative Names
K 22.175
Area of Interest
Autophagy, Cancer, Metabolism
CAS Number
658084-64-1
Chemical Formula
C₂₄H₂₉NO
Molecular Weight
391.5 g/mol
Purity
≥ 98%
Pathway
mTOR
Target
AMPK

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
FK-866
Catalog #
100-0264, 100-0263
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
FK-866
Catalog #
100-0264, 100-0263
Lot #
All
Language
English

Resources and Publications

Publications (6)

Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage. A. M. Cameron et al. Nature immunology 2019

Abstract

The adoption of Warburg metabolism is critical for the activation of macrophages in response to lipopolysaccharide. Macrophages stimulated with lipopolysaccharide increase their expression of nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD+ salvage, and loss of NAMPT activity alters their inflammatory potential. However, the events that lead to the cells' becoming dependent on NAD+ salvage remain poorly defined. We found that depletion of NAD+ and increased expression of NAMPT occurred rapidly after inflammatory activation and coincided with DNA damage caused by reactive oxygen species (ROS). ROS produced by complex III of the mitochondrial electron-transport chain were required for macrophage activation. DNA damage was associated with activation of poly(ADP-ribose) polymerase, which led to consumption of NAD+. In this setting, increased NAMPT expression allowed the maintenance of NAD+ pools sufficient for glyceraldehyde-3-phosphate dehydrogenase activity and Warburg metabolism. Our findings provide an integrated explanation for the dependence of inflammatory macrophages on the NAD+ salvage pathway.
Loss of NAMPT in aging retinal pigment epithelium reduces NAD+ availability and promotes cellular senescence. R. N. Jadeja et al. Aging 2018 jun

Abstract

Retinal pigment epithelium (RPE) performs numerous functions critical to retinal health and visual function. RPE senescence is a hallmark of aging and degenerative retinal disease development. Here, we evaluated the temporal expression of key nicotinamide adenine dinucleotide (NAD+)-biosynthetic genes and associated levels of NAD+, a principal regulator of energy metabolism and cellular fate, in mouse RPE. NAD+ levels declined with age and correlated directly with decreased nicotinamide phosphoribosyltransferase (NAMPT) expression, increased expression of senescence markers (p16INK4a, p21Waf/Cip1, ApoJ, CTGF and $\beta$-galactosidase) and significant reductions in SIRT1 expression and activity. We simulated in vitro the age-dependent decline in NAD+ and the related increase in RPE senescence in human (ARPE-19) and mouse primary RPE using the NAMPT inhibitor FK866 and demonstrated the positive impact of NAD+-enhancing therapies on RPE cell viability. This, we confirmed in vivo in the RPE of mice injected sub-retinally with FK866 in the presence or absence of nicotinamide mononucleotide. Our data confirm the importance of NAD+ to RPE cell biology normally and in aging and demonstrate the potential utility of therapies targeting NAMPT and NAD+ biosynthesis to prevent or alleviate consequences of RPE senescence in aging and/or degenerative retinal diseases in which RPE dysfunction is a crucial element.
FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. S. Schuster et al. Biochemical and biophysical research communications 2015 mar

Abstract

BACKGROUND Nicotinamide phosphoribosyltransferase (NAMPT) is the key enzyme of the NAD salvage pathway starting from nicotinamide. Cancer cells have an increased demand for NAD due to their high proliferation and DNA repair rate. Consequently, NAMPT is considered as a putative target for anti-cancer therapies. There is evidence that AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) become dysregulated during the development of hepatocellular carcinoma (HCC). Here, we investigated the effects of NAMPT inhibition by its specific inhibitor FK866 on the viability of hepatocarcinoma cells and analyzed the effects of FK866 on the nutrient sensor AMPK and mTOR complex1 (mTORC1) signaling. RESULTS FK866 markedly decreased NAMPT activity and NAD content in hepatocarcinoma cells (Huh7 cells, Hep3B cells) and led to delayed ATP reduction which was associated with increased cell death. These effects could be abrogated by administration of nicotinamide mononucleotide (NMN), the enzyme product of NAMPT. Our results demonstrated a dysregulation of the AMPK/mTOR pathway in hepatocarcinoma cells compared to non-cancerous hepatocytes with a higher expression of mTOR and a lower AMPK$\alpha$ activation in hepatocarcinoma cells. We found that NAMPT inhibition by FK866 significantly activated AMPK$\alpha$ and inhibited the activation of mTOR and its downstream targets p70S6 kinase and 4E-BP1 in hepatocarcinoma cells. Non-cancerous hepatocytes were less sensitive to FK866 and did not show changes in AMPK/mTOR signaling after FK866 treatment. CONCLUSION Taken together, these findings reveal an important role of the NAMPT-mediated NAD salvage pathway in the energy homeostasis of hepatocarcinoma cells and suggest NAMPT inhibition as a potential treatment option for HCC.